Can analysts adopt a bullish outlook for Cara Therapeutics, Inc. (NASDAQ:CARA)?

July 11, 2018 - By Rene Reddy

Cara Therapeutics, Inc. (NASDAQ:CARA) LogoInvestors sentiment decreased to 0.83 in 2018 Q1. Its down 0.10, from 0.93 in 2017Q4. It turned negative, as 13 investors sold Cara Therapeutics, Inc. shares while 27 reduced holdings. 15 funds opened positions while 18 raised stakes. 15.62 million shares or 1.17% less from 15.80 million shares in 2017Q4 were reported.
Captrust Fin reported 100 shares stake. Amer Intl Group Inc Inc Inc has 0% invested in Cara Therapeutics, Inc. (NASDAQ:CARA). Vanguard Gp invested in 0% or 1.23 million shares. 691,735 are held by Fmr Ltd Liability Company. Daiwa Securities Gru invested in 0% or 180 shares. 22,300 were reported by Rothschild Investment Il. State Street Corp has invested 0% in Cara Therapeutics, Inc. (NASDAQ:CARA). Tower Rech Cap Ltd (Trc) invested in 0% or 93 shares. 40,475 were reported by California State Teachers Retirement Systems. Bnp Paribas Arbitrage invested in 5,698 shares or 0% of the stock. Baldwin Brothers Ma invested in 23,354 shares. C Wide Gru Holdings A S holds 0.04% of its portfolio in Cara Therapeutics, Inc. (NASDAQ:CARA) for 231,775 shares. Price T Rowe Associate Inc Md holds 479,275 shares. Moreover, Td Asset Mngmt has 0% invested in Cara Therapeutics, Inc. (NASDAQ:CARA). 326,654 were accumulated by Jpmorgan Chase And Communications.

Since January 24, 2018, it had 0 insider buys, and 7 selling transactions for $778,740 activity. 5,400 shares were sold by CHALMERS DEREK T, worth $81,000.

Cara Therapeutics, Inc. (NASDAQ:CARA) Ratings Coverage

Among 5 analysts covering Cara Therapeutics (NASDAQ:CARA), 5 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Cara Therapeutics had 9 analyst reports since January 19, 2018 according to SRatingsIntel. The firm has “Buy” rating by H.C. Wainwright given on Monday, March 19. The stock of Cara Therapeutics, Inc. (NASDAQ:CARA) has “Buy” rating given on Thursday, March 15 by Canaccord Genuity. The rating was reinitiated by H.C. Wainwright on Monday, March 12 with “Buy”. Laidlaw maintained the stock with “Buy” rating in Thursday, May 24 report. On Monday, February 12 the stock rating was upgraded by Janney Capital to “Buy”. The rating was maintained by H.C. Wainwright on Friday, May 11 with “Buy”. The firm earned “Buy” rating on Wednesday, May 23 by H.C. Wainwright. On Friday, June 29 the stock rating was maintained by Canaccord Genuity with “Buy”. Below is a list of Cara Therapeutics, Inc. (NASDAQ:CARA) latest ratings and price target changes.

29/06/2018 Broker: Canaccord Genuity Old Rating: Buy New Rating: Buy Old Target: $21 New Target: $22 Maintain
24/05/2018 Broker: Laidlaw Rating: Buy New Target: $26.0000 Maintain
23/05/2018 Broker: H.C. Wainwright Rating: Buy New Target: $24.0000 Maintain
11/05/2018 Broker: H.C. Wainwright Rating: Buy New Target: $22.0000 Maintain
19/03/2018 Broker: H.C. Wainwright Rating: Buy New Target: $22.0 Maintain
15/03/2018 Broker: Canaccord Genuity Rating: Buy New Target: $22.0 Maintain
12/03/2018 Broker: H.C. Wainwright Rating: Buy New Target: $22 Reinitiate
12/02/2018 Broker: Janney Capital Old Rating: Neutral New Rating: Buy Old Target: $21 Upgrade
19/01/2018 Broker: Seaport Global Rating: Buy New Target: $27 Initiates Coverage On

The stock increased 4.25% or $0.88 during the last trading session, reaching $21.6. About 812,636 shares traded. Cara Therapeutics, Inc. (NASDAQ:CARA) has risen 1.86% since July 11, 2017 and is uptrending. It has underperformed by 10.71% the S&P500.

Cara Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing chemical entities designed to alleviate pain and pruritus by selectively targeting kappa opioid receptors in the United States. The company has market cap of $706.32 million. It is developing product candidates that target the body's peripheral nervous system. It currently has negative earnings. The companyÂ’s lead product candidate comprises I.V.

More notable recent Cara Therapeutics, Inc. (NASDAQ:CARA) news were published by: Streetinsider.com which released: “Cara Therapeutics (CARA) Announces Dosing of Patients in Phase 2 Trial of Oral KORSUVA for Pruritus in Stage III-V …” on July 11, 2018, also Prnewswire.com with their article: “Canadian Cannabis Market is Projected to Rival California’s” published on July 11, 2018, Nasdaq.com published: “Here’s Why Cara Therapeutics Jumped 26.3% in May” on June 14, 2018. More interesting news about Cara Therapeutics, Inc. (NASDAQ:CARA) were released by: Streetinsider.com and their article: “Pre-Open Movers 06/27: (DFBG) (CARA) (I) Higher; (AQXP) (PTIE) (DRRX) Lower (more…)” published on June 27, 2018 as well as Nasdaq.com‘s news article titled: “Cara Therapeutics Announces Dosing of Patients in Phase 2 Trial of Oral KORSUVAâ„¢ (CR845/difelikefalin) for …” with publication date: July 11, 2018.

Cara Therapeutics, Inc. (NASDAQ:CARA) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.